Alterity Therapeutics - ADR opened lower at $2.28, compared with its previous close of $2.31. In the last trading session, the stock traded between $2.04 and $2.28. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Alterity Therapeutics - ADR is now worth
$ 18.14
Resulting in a loss of
$ 81.86 (81.86%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.21 (-8.92%)
Day High
$2.28
Day Low
$2.04
Day Open
$2.28
Prev Close
$2.31
Volume
71,326
1W Return
-14.58%
1M Return
-29.51%
3M Return
-55.01%
6M Return
-56.17%
1Y Return
-42.67%
Market Cap ($ Mn)
40
PE Ratio
-
PB Ratio
3.22
PEG Ratio
-
ROE
-75.04%
ROCE
-58.56%
EPS (TTM)
-
1 Week
-14.58%
1 Month
-29.51%
3 Months
-55.01%
6 Months
-56.17%
9 Months
-40.40%
Alterity Therapeutics CEO to speak at Cantor Global Healthcare Conference
David Stamler, CEO, will speak at the Cantor Global Healthcare Conference 2026 on September 11. The fireside chat is scheduled for 10:20 am ET and will be webcast live. Alterity is preparing to initiate a Phase 3 pivotal trial for its lead asset ATH434. The company focuses on disease-modifying therapies for Multiple System Atrophy (MSA).
2mo agoAlterity Therapeutics secures US patent for ATH434 extending protection to 2045
Alterity Therapeutics Limited secured a USPTO patent for ATH434 on August 12, 2026, covering its crystalline mesylate salt form. The IP protection extends to at least 2045, supporting Phase 3 trial plans for Multiple System Atrophy by year-end 2026. The patent also opens avenues for development in Parkinson's disease, leveraging existing Fast Track and Orphan Drug designations.
3mo agoCraig-Hallum initiates coverage on Alterity Therapeutics with Buy rating
Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a $12 price target. This marks the firm's first public assessment of the company, potentially increasing investor visibility for the biotech stock.
3mo agoAlterity Therapeutics Q4 Results: FDA aligns on ATH434 Phase 3
Alterity Therapeutics Limited achieved a key regulatory milestone with the FDA agreeing to a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy. The company reported A$37.3 million in cash as of June 30, 2026, and received an A$3.98 million R&D tax refund. Strategic partnering discussions are underway to support the upcoming trial initiation targeted for year-end 2026.
3mo agoAlterity Therapeutics CEO to attend BTIG Biotechnology Conference
Alterity Therapeutics Limited announced that CEO David Stamler will attend the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026, to host investor meetings. The company is advancing its lead asset ATH434 into a Phase 3 pivotal trial for Multiple System Atrophy following positive Phase 2 results.
3mo agoFDA confirms single pivotal trial path for ATH434 in MSA
Alterity Therapeutics received official meeting minutes from the FDA confirming that a single pivotal Phase 3 trial plus confirmatory evidence could support approval of ATH434 for the treatment of Multiple System Atrophy (MSA). The FDA agreed with the proposed Phase 3 trial design, including the primary endpoint of the 11-item UMSARS Part I rating scale. The Phase 3 study is expected to enroll approximately 200 patients and is on track to initiate by year-end 2026.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Alterity Therapeutics - ADR is now worth
$ 18.14
Resulting in a loss of
$ 81.86 (81.86%)
Note: Past profits do not guarantee future returns.
